Pharma BD Deal Intelligence
GSK acquired Bellus Health for $2B.
GSK to buy Bellus Health for $2 billion gaining camlipixant P2X3 antagonist in Phase III for chronic cough.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
GSK acquired Bellus Health for $2B.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| GSK plc / Bellus Health Inc. (this deal) | 2003 | $2.0B | 68 |
| GSK plc / SmithKline Beecham | 2000 | $12.0B | 79 |
| GSK plc / Pfizer Inc. | 2018 | $0.0M | 77 |
| GSK plc / Novartis AG | 2014 | $16.0B | 76 |
| GSK plc / Hansoh Pharmaceutical Group Co. Ltd. | 2023 | $1.7B | 74 |
| GSK plc / Nuvalent, Inc. | 2026 | $10.6B | 70 |
| GSK plc / Sierra Oncology Inc. | 2022 | $1.9B | 70 |
← Browse all deals · How we score deals
More: 2003 deals · GSK plc deals · Oncology deals